What's Happening?
ImmunityBio has initiated a Phase 2 study to evaluate the efficacy of ANKTIVA, an IL-15 agonist, in treating long COVID. The study aims to assess ANKTIVA's ability to boost NK cell responses and improve immune function in patients experiencing long COVID symptoms. Long COVID affects approximately one in five Americans who had COVID-19, presenting a significant public health challenge with no established treatments. The study will explore ANKTIVA's potential to enhance immune responses and facilitate viral clearance, offering a new therapeutic option for this chronic condition.
AD
Why It's Important?
Long COVID remains a major health concern, impacting the quality of life for many individuals. The development of effective treatments is crucial for addressing the long-term effects of COVID-19. ANKTIVA's potential to improve immune function and alleviate symptoms could provide relief for patients and reduce the burden on healthcare systems. This study represents a significant step in finding solutions for long COVID, potentially leading to new treatment protocols and improving patient outcomes.
What's Next?
The study will recruit up to 40 participants to evaluate the safety and efficacy of ANKTIVA. Results from this study could pave the way for further clinical trials and regulatory approval, expanding treatment options for long COVID. ImmunityBio's research may also contribute to broader understanding of immune responses in viral infections, influencing future therapeutic strategies.
